Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SANDEEP BANSAL

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1215105267
CMS profile
99969
Location
DU BOIS, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$244,810.48

302 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 2 of 7; records 51–100 of 302 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SANDEEP BANSAL

NPI 1215105267 · CMS profile ID 99969

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

DU BOIS, PA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 7; records 51–100 of 302 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1215105267?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SANDEEP BANSAL, NPI 1215105267, CMS profile ID 99969. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 302 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1215105267?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). SANDEEP BANSAL, NPI 1215105267, CMS profile ID 99969. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 7; records 51–100 of 302 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1215105267?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
SANDEEP BANSAL, NPI 1215105267, CMS profile ID 99969, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 7; records 51–100 of 302 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1215105267?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

302 matching records · $244,810.48 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 302 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 302.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $1,050.0011/14/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104698158 CMS
GENZYME CORPORATION $23.7211/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139825448 CMS
Regeneron Healthcare Solutions, Inc. $33.1111/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114004991 CMS
Regeneron Healthcare Solutions, Inc. $118.0811/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114004993 CMS
GlaxoSmithKline, LLC. $44.4611/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116656555 CMS
Mylan Specialty L.P. $61.9011/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147359994 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $27.2611/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117917397 CMS
GlaxoSmithKline, LLC. $3,900.0011/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115884753 CMS
AstraZeneca Pharmaceuticals LP $20.8411/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105623791 CMS
GlaxoSmithKline, LLC. $1,300.0011/06/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116026850 CMS
GlaxoSmithKline, LLC. $41.7911/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116298086 CMS
GlaxoSmithKline, LLC. $264.0311/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116500387 CMS
GlaxoSmithKline, LLC. $31.0211/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116532722 CMS
GlaxoSmithKline, LLC. $332.0911/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116733904 CMS
GlaxoSmithKline, LLC. $13.2811/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116555875 CMS
AstraZeneca Pharmaceuticals LP $15.9010/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105398944 CMS
Regeneron Healthcare Solutions, Inc. $5,428.0010/31/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114004987 CMS
Regeneron Healthcare Solutions, Inc. $8,768.0010/31/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114004989 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,261.0010/30/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137480276 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $82.4410/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117917401 CMS
Regeneron Healthcare Solutions, Inc. $1,180.5010/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114004981 CMS
Regeneron Healthcare Solutions, Inc. $451.3310/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114004983 CMS
Regeneron Healthcare Solutions, Inc. $1,043.9010/26/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114004985 CMS
Insmed, Inc. $22.0510/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089559230 CMS
Regeneron Healthcare Solutions, Inc. $114.8610/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114004979 CMS
Actelion Pharmaceuticals US, Inc. $15.8210/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078908833 CMS
Regeneron Healthcare Solutions, Inc. $55.4310/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114004977 CMS
AstraZeneca Pharmaceuticals LP $19.2110/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105424575 CMS
AstraZeneca Pharmaceuticals LP $537.0010/19/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104786738 CMS
GENZYME CORPORATION $32.7310/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139825440 CMS
Novo Nordisk Inc $125.0010/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096890938 CMS
Regeneron Healthcare Solutions, Inc. $1,670.0010/17/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114004975 CMS
GENZYME CORPORATION $124.9710/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139825572 CMS
GENZYME CORPORATION $8,768.0010/16/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139825574 CMS
GENZYME CORPORATION $104.3410/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139825576 CMS
GENZYME CORPORATION $1,222.8110/16/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139825578 CMS
GlaxoSmithKline, LLC. $1,300.0010/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116357324 CMS
GlaxoSmithKline, LLC. $1,300.0010/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116415129 CMS
GlaxoSmithKline, LLC. $3,900.0010/15/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116621541 CMS
GlaxoSmithKline, LLC. $19.8810/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116327594 CMS
Noah Medical Corporation $3,200.0010/08/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143649831 CMS
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $10.7210/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1080693630 CMS
AstraZeneca Pharmaceuticals LP $21.6310/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104330720 CMS
GlaxoSmithKline, LLC. $5.0010/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115940119 CMS
GlaxoSmithKline, LLC. $106.0810/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116266217 CMS
GlaxoSmithKline, LLC. $104.3410/03/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116532516 CMS
Electromed, Inc. $16.9610/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137879255 CMS
GlaxoSmithKline, LLC. $1,300.0009/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1115818548 CMS
GlaxoSmithKline, LLC. $3,900.0009/30/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116503425 CMS
Regeneron Healthcare Solutions, Inc. $18.2009/30/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1114004973 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $94,744.72 173
PY2020 $88,128.38 85
PY2021 $177,262.19 214
PY2022 $265,557.47 314
PY2023 $275,241.16 380
PY2024 $244,810.48 302
PY2025 $280,538.04 298

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,140,697.05 330
PY2024 Recipient $1,379.64 7
PY2024 Principal investigator $2,630,112.11 233
PY2023 Principal investigator $1,341,166.54 108
PY2022 Principal investigator $508,223.05 63
PY2021 Principal investigator $499,768.78 77
PY2020 Principal investigator $154,747.10 16
PY2019 Principal investigator $173,088.95 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

330 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $20,867.98 12/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO) No dispute reported 06/30/2026 1185555487
Principal investigator 1 SANOFI US SERVICES INC. $3,982.00 12/22/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226131096
Principal investigator 1 AstraZeneca Pharmaceuticals LP $874.61 12/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
A Phase III Multicentre Randomised Double blind Chronic dosing Parallel group Placebo controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease COPD with a History of COPD Exacerbations OBERON No dispute reported 06/30/2026 1185555479
Principal investigator 1 PFIZER INC. $1,339.39 12/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOC CENTRAL PA
AN INTERVENTIONAL PHASE 23 RANDOMIZED DOUBLEBLIND THIRD PARTYUNBLINDED PLACEBOCONTROLLED PARALLELGROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH MODERATETOSEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD No dispute reported 06/30/2026 1228814920
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,500.00 12/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184277248
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $750.00 12/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184277250
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,500.00 12/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184277252
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 12/17/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640897
Principal investigator 1 Boehringer Ingelheim International GmbH $547.50 12/17/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640899
Principal investigator 1 Boehringer Ingelheim International GmbH $20.88 12/17/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640901
Principal investigator 1 Boehringer Ingelheim International GmbH $9.30 12/17/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640903
Principal investigator 1 Boehringer Ingelheim International GmbH $60.00 12/17/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640905
Principal investigator 1 Genentech, Inc. $1,120.00 12/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES O
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211586984
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,131.60 12/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations No dispute reported 06/30/2026 1185555473
Principal investigator 1 Genentech, Inc. $1,721.66 12/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES O
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211586979
Principal investigator 1 Genentech, Inc. $3,450.00 12/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211587149
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $651.00 12/05/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220812828
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $10,712.20 12/05/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220812874
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,300.00 12/05/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220812876
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $160.00 12/05/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220812878
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 12/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640889
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 12/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640891
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 12/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640893
Principal investigator 1 Boehringer Ingelheim International GmbH $45.81 12/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220641003
Principal investigator 1 AstraZeneca Pharmaceuticals LP $14,033.10 11/26/2025 Non-covered Recipient Entity
CLINICAL LABORATORIES OF LINCOLN
A Multicentre, Parallel-group, Phase IIb, Randomised, Double blind, Placebo-controlled, 4-Arm, 24-Week Study to Evaluate the Efficacy and Safety of AZD6793 Tablets in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (PRESTO) No dispute reported 06/30/2026 1185555485
Principal investigator 1 Boehringer Ingelheim International GmbH $2.50 11/26/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640919
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 11/26/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640921
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 11/26/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640923
Principal investigator 1 Boehringer Ingelheim International GmbH $2.50 11/24/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640913
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 11/24/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640915
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 11/24/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640917
Principal investigator 1 SANOFI US SERVICES INC. $21,114.14 11/24/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226131083
Principal investigator 1 SANOFI US SERVICES INC. $50.00 11/24/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226131086
Principal investigator 1 SANOFI US SERVICES INC. $6,500.00 11/24/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226131089
Principal investigator 1 SANOFI US SERVICES INC. $1,620.00 11/24/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226131091
Principal investigator 1 AstraZeneca Pharmaceuticals LP $52,050.00 11/23/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
Randomized Double blind Placebo controlled Parallel Group Multicenter Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD No dispute reported 06/30/2026 1185555495
Principal investigator 1 Boehringer Ingelheim International GmbH $116.60 11/19/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640895
Principal investigator 1 GlaxoSmithKline, LLC. $15,000.00 11/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVEST No dispute reported 06/30/2026 1192175238
Principal investigator 1 GlaxoSmithKline, LLC. $548.00 11/10/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192179358
Principal investigator 1 Boehringer Ingelheim International GmbH $0.87 11/07/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640867
Principal investigator 1 Boehringer Ingelheim International GmbH $4.72 11/07/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640869
Principal investigator 1 Boehringer Ingelheim International GmbH $0.70 11/07/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640871
Principal investigator 1 Boehringer Ingelheim International GmbH $9.60 11/07/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640873
Principal investigator 1 Boehringer Ingelheim International GmbH $11.39 11/07/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640875
Principal investigator 1 Genentech, Inc. $200.00 11/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211587141
Principal investigator 1 GlaxoSmithKline, LLC. $435.00 11/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192173341
Principal investigator 1 Pulmonx Corporation $1,193.75 11/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES
Zephyr Valve Registry No dispute reported 06/30/2026 1199558957
Principal investigator 1 Genentech, Inc. $55,369.00 11/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211587144
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 11/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640883
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 11/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640885
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 11/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640887
Principal investigator 1 Boehringer Ingelheim International GmbH $45.81 11/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220641011
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,000.00 10/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184253973
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 10/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184253975
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $80.00 10/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184253977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $40.00 10/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184253979
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 10/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184253981
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 10/27/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220641005
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $650.00 10/27/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220812820
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $182.95 10/27/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220812822
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $21,500.00 10/27/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220812824
Principal investigator 1 SANOFI US SERVICES INC. $3,175.00 10/27/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226131080
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,025.04 10/22/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220812872
Principal investigator 1 GENZYME CORPORATION $21,344.00 10/20/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
Evaluate how dupilumab can alter the trajectory of COPD by modifying disease progression No dispute reported 06/30/2026 1226131075
Principal investigator 1 SANOFI US SERVICES INC. $4,364.00 10/20/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226131072
Principal investigator 1 AstraZeneca UK Limited $750.00 10/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
BRISOTE A Multicentre Randomised DoubleBlind Parallel Group ActiveControlled Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium Dose Inhaled Corticosteroid Plus Long acting 2 Agonist No dispute reported 06/30/2026 1185555489
Principal investigator 1 GlaxoSmithKline, LLC. $6,829.24 10/15/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
REAL-WORLD EFFECTIVENESS OF MEPOLIZUMAB IN TREATING CHRONIC OBSTRUCTIV No dispute reported 06/30/2026 1192175230
Principal investigator 1 SANOFI US SERVICES INC. $2,100.00 10/14/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226131068
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $650.00 10/08/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220812826
Principal investigator 1 Pulmonx Corporation $1,567.00 10/08/2025 Non-covered Recipient Entity
WCG IRB LLC
Zephyr Valve Registry No dispute reported 06/30/2026 1199558854
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $21,405.40 10/06/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220812870
Principal investigator 1 GlaxoSmithKline, LLC. $401.50 10/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192179376
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 10/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640877
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 10/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640879
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 10/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640881
Principal investigator 1 Boehringer Ingelheim International GmbH $45.81 10/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220641009
Principal investigator 1 Verona Pharma, Inc. $11,825.00 10/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES O
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891401
Principal investigator 1 Verona Pharma, Inc. $1,500.00 10/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES O
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891403
Principal investigator 1 Verona Pharma, Inc. $1,300.00 10/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES O
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891405
Principal investigator 1 SANOFI US SERVICES INC. $3,806.00 09/29/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226131062
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $434.00 09/25/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220812818
Principal investigator 1 Boehringer Ingelheim International GmbH $757.90 09/24/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640843
Principal investigator 1 Boehringer Ingelheim International GmbH $1,606.00 09/24/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640845
Principal investigator 1 Boehringer Ingelheim International GmbH $67.28 09/24/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640847
Principal investigator 1 Boehringer Ingelheim International GmbH $327.75 09/24/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640849
Principal investigator 1 Boehringer Ingelheim International GmbH $12.60 09/24/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640851
Principal investigator 1 Boehringer Ingelheim International GmbH $21.70 09/24/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640853
Principal investigator 1 Boehringer Ingelheim International GmbH $155.00 09/24/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640855
Principal investigator 1 Boehringer Ingelheim International GmbH $61.07 09/24/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220640995
Principal investigator 1 Boehringer Ingelheim International GmbH $20.73 09/24/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220640997
Principal investigator 1 Boehringer Ingelheim International GmbH $1.68 09/24/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220640999
Principal investigator 1 Boehringer Ingelheim International GmbH $7.50 09/24/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220641001
Principal investigator 1 GlaxoSmithKline, LLC. $182.95 09/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192177040
Principal investigator 1 GlaxoSmithKline, LLC. $12,000.00 09/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192173338
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 09/19/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTIC No dispute reported 06/30/2026 1192175234
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,001.35 09/18/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220812864
Principal investigator 1 SANOFI US SERVICES INC. $4,313.00 09/15/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226131030
Principal investigator 1 SANOFI US SERVICES INC. $3,756.00 09/15/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226131033
Principal investigator 1 GlaxoSmithKline, LLC. $11,152.00 09/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS T No dispute reported 06/30/2026 1192175226
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $40.00 09/10/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220812866
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $80.00 09/10/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220812868
Principal investigator 1 Boehringer Ingelheim International GmbH $5.01 09/08/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640907
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 09/08/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640909
Principal investigator 1 Boehringer Ingelheim International GmbH $4.21 09/08/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640911
Principal investigator 1 GlaxoSmithKline, LLC. $603.00 09/08/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192123568
Principal investigator 1 Boehringer Ingelheim International GmbH $0.70 09/04/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640857
Principal investigator 1 Boehringer Ingelheim International GmbH $9.60 09/04/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640859
Principal investigator 1 Boehringer Ingelheim International GmbH $11.39 09/04/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640861
Principal investigator 1 Boehringer Ingelheim International GmbH $0.87 09/04/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640863
Principal investigator 1 Boehringer Ingelheim International GmbH $4.72 09/04/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640865
Principal investigator 1 Boehringer Ingelheim International GmbH $0.87 09/04/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640925
Principal investigator 1 Boehringer Ingelheim International GmbH $4.72 09/04/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640927
Principal investigator 1 Boehringer Ingelheim International GmbH $0.70 09/04/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640929
Principal investigator 1 Boehringer Ingelheim International GmbH $9.60 09/04/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640931
Principal investigator 1 Boehringer Ingelheim International GmbH $11.39 09/04/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640933
Principal investigator 1 SANOFI US SERVICES INC. $1,252.00 09/03/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226131042
Principal investigator 1 SANOFI US SERVICES INC. $6,846.00 09/03/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226131044
Principal investigator 1 SANOFI US SERVICES INC. $92.00 09/03/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226131049
Principal investigator 1 SANOFI US SERVICES INC. $45.36 09/03/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226131051
Principal investigator 1 SANOFI US SERVICES INC. $200.00 09/03/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226131054
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 09/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640821
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 09/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640823
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 09/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640825
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 09/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640827
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 09/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640829
Principal investigator 1 Boehringer Ingelheim International GmbH $45.81 09/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220641007
Principal investigator 1 Genentech, Inc. $750.00 08/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211587091
Principal investigator 1 Genentech, Inc. $4,867.00 08/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211587094
Principal investigator 1 Genentech, Inc. $331.00 08/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211587099
Principal investigator 1 Genentech, Inc. $2,000.00 08/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211587103
Principal investigator 1 Genentech, Inc. $678.40 08/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211587107
Principal investigator 1 Genentech, Inc. $500.00 08/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211587111
Principal investigator 1 Genentech, Inc. $1,500.00 08/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211587115
Principal investigator 1 Genentech, Inc. $750.00 08/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211587119
Principal investigator 1 Genentech, Inc. $2,405.40 08/27/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211587124
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 08/26/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220640993
Principal investigator 1 SANOFI US SERVICES INC. $750.00 08/25/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226131038
Principal investigator 1 SANOFI US SERVICES INC. $126.54 08/25/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226131057
Principal investigator 1 Genentech, Inc. $360.00 08/22/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211587131
Principal investigator 1 GlaxoSmithKline, LLC. $4,000.00 08/22/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192177036
Principal investigator 1 GlaxoSmithKline, LLC. $372.00 08/20/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192179368
Principal investigator 1 SANOFI US SERVICES INC. $750.00 08/18/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226131018
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $20,136.20 08/14/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220812854
Principal investigator 1 SANOFI US SERVICES INC. $75.00 08/11/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226131013
Principal investigator 1 SANOFI US SERVICES INC. $75.00 08/11/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226131025
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $40.00 08/07/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220812856
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $40.00 08/07/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220812858
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,300.00 08/07/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220812860
Principal investigator 1 GlaxoSmithKline, LLC. $4,224.00 08/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
A MULTI-CENTRE, SINGLE ARM, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE No dispute reported 06/30/2026 1192123577
Principal investigator 1 SANOFI US SERVICES INC. $12,532.00 08/04/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226130986
Principal investigator 1 SANOFI US SERVICES INC. $65.00 08/04/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226130991
Principal investigator 1 SANOFI US SERVICES INC. $50.00 08/04/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226130996
Principal investigator 1 SANOFI US SERVICES INC. $75.00 08/04/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226131004
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 08/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640809
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 08/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640811
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 08/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640813
Principal investigator 1 Boehringer Ingelheim International GmbH $785.00 08/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640815
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640817
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640819
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 08/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220640949
Principal investigator 1 GlaxoSmithKline, LLC. $2,239.80 08/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192123562
Principal investigator 1 GlaxoSmithKline, LLC. $3,466.00 08/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192123583
Principal investigator 1 GlaxoSmithKline, LLC. $14,500.00 08/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
A MULTICENTRE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FIND No dispute reported 06/30/2026 1192175251
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,000.00 07/29/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220812852
Principal investigator 1 Boehringer Ingelheim International GmbH $174.90 07/28/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640831
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 07/28/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640833
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 07/28/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640835
Principal investigator 1 Boehringer Ingelheim International GmbH $9.28 07/28/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640837
Principal investigator 1 Boehringer Ingelheim International GmbH $65.55 07/28/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640839
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 07/28/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640841
Principal investigator 1 Boehringer Ingelheim International GmbH $359.64 07/28/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220640981
Principal investigator 1 Boehringer Ingelheim International GmbH $328.50 07/28/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220640983
Principal investigator 1 Boehringer Ingelheim International GmbH $305.35 07/28/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220640985
Principal investigator 1 Boehringer Ingelheim International GmbH $82.92 07/28/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220640987
Principal investigator 1 Boehringer Ingelheim International GmbH $20.16 07/28/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220640989
Principal investigator 1 Boehringer Ingelheim International GmbH $71.50 07/28/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220640991
Principal investigator 1 SANOFI US SERVICES INC. $75.00 07/28/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226130999
Principal investigator 1 SANOFI US SERVICES INC. $1,575.00 07/28/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226131007
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,904.00 07/25/2025 Non-covered Recipient Entity
CLINICAL LABORATORIES OF LINCOLN
A Multicenter Open label Phase 3B Efficacy and Safety Study of Tezepelumab 210 mg Administered Subcutaneously to Reduce Oral Corticosteroid Use and Asthma Exacerbations in Adult Subjects with Severe Asthma on High Dose Inhaled Corticosteroid plus Long acting B2 Agonist and Chronic Oral Corticosteroid Therapy No dispute reported 06/30/2026 1185555493
Principal investigator 1 Genentech, Inc. $898.00 07/25/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211587135
Principal investigator 1 GlaxoSmithKline, LLC. $1,337.50 07/25/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192179355
Principal investigator 1 SANOFI US SERVICES INC. $900.00 07/21/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226130979
Principal investigator 1 Genentech, Inc. $33,437.00 07/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211587127
Principal investigator 1 SANOFI US SERVICES INC. $4,500.00 07/14/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous SAR443765 in Adult Participants With Moderate to Severe Asthma No dispute reported 06/30/2026 1226130966
Principal investigator 1 SANOFI US SERVICES INC. $2,100.00 07/14/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226130983
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $23,445.05 07/10/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220812850
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,200.00 07/09/2025 Non-covered Recipient Entity
CLINICAL LABORATORIES OF LINCOLN
A Phase 2 randomized double blind placebo controlled dose regimen range finding study to assess efficacy and safety of subcutaneous tozorakimab in adult participants with uncontrolled asthma on medium to high dose inhaled corticosteroids No dispute reported 06/30/2026 1185555497
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $40.00 07/07/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220812848
Principal investigator 1 SANOFI US SERVICES INC. $75.00 07/07/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226130970
Principal investigator 1 SANOFI US SERVICES INC. $63,377.00 07/07/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226130973
Principal investigator 1 SANOFI US SERVICES INC. $20,014.14 07/02/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226130962
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 07/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640803
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 07/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640805
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 07/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640807
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 07/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220640947
Principal investigator 1 PFIZER INC. $12,500.00 06/26/2025 Non-covered Recipient Entity
Clinical Research Associates of Central PA LLC
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA No dispute reported 06/30/2026 1228851565
Principal investigator 1 Genentech, Inc. $40.00 06/25/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES O
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211586963
Principal investigator 1 Genentech, Inc. $320.00 06/25/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES O
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211586975
Principal investigator 1 SANOFI US SERVICES INC. $2,608.00 06/23/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226130958
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,000.00 06/20/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
PhII - BI 1839100 in IPF associated with chronic cough No dispute reported 06/30/2026 1220812884
Principal investigator 1 GlaxoSmithKline, LLC. $690.00 06/19/2025 Non-covered Recipient Entity
ADVARRA
A PHASE 4, 52-WEEK (PRIMARY ANALYSIS AT 24-WEEKS), RANDOMIZED, STRATIF No dispute reported 06/30/2026 1192123588
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,211.10 06/17/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
PhII - BI 1839100 in IPF associated with chronic cough No dispute reported 06/30/2026 1220812882
Principal investigator 1 GlaxoSmithKline, LLC. $649.80 06/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192179363
Principal investigator 1 SANOFI US SERVICES INC. $2,868.75 06/16/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226130951
Principal investigator 1 SANOFI US SERVICES INC. $157.00 06/16/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226130955
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $500.00 06/12/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220812844
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $500.00 06/12/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220812846
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $21,148.90 06/11/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220812842
Principal investigator 1 SANOFI US SERVICES INC. $3,483.90 06/09/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226130942
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $500.00 06/06/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220812862
Principal investigator 1 Genentech, Inc. $2,694.00 06/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211587075
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 06/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640779
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 06/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640781
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 06/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640783
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 06/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220640945
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,300.00 06/01/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220812840
Principal investigator 1 AstraZeneca UK Limited $14,062.00 05/28/2025 Non-covered Recipient Entity
CLINICAL LABORATORIES OF LINCOLN
BRISOTE A Multicentre Randomised DoubleBlind Parallel Group ActiveControlled Phase 3b Study to Evaluate the Efficacy and Safety of Benralizumab 30 mg SC in Eosinophilic Asthma Patients Uncontrolled on Medium Dose Inhaled Corticosteroid Plus Long acting 2 Agonist No dispute reported 06/30/2026 1185555491
Principal investigator 1 Boehringer Ingelheim International GmbH $174.90 05/27/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640791
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 05/27/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640793
Principal investigator 1 Boehringer Ingelheim International GmbH $401.50 05/27/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640795
Principal investigator 1 Boehringer Ingelheim International GmbH $9.28 05/27/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640797
Principal investigator 1 Boehringer Ingelheim International GmbH $65.55 05/27/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640799
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 05/27/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640801
Principal investigator 1 Boehringer Ingelheim International GmbH $11.66 05/27/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220640977
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 05/27/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220640979
Principal investigator 1 SANOFI US SERVICES INC. $140.97 05/27/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226130930
Principal investigator 1 SANOFI US SERVICES INC. $123,322.41 05/27/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226130933
Principal investigator 1 SANOFI US SERVICES INC. $2,100.00 05/27/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226130938
Principal investigator 1 Genentech, Inc. $392.85 05/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211587065
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 05/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192177031
Principal investigator 1 GlaxoSmithKline, LLC. $1,800.00 05/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT No dispute reported 06/30/2026 1192175247
Principal investigator 1 GlaxoSmithKline, LLC. $790.00 05/16/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192175255
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $78,426.30 05/13/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220812838
Principal investigator 1 SANOFI US SERVICES INC. $157.00 05/12/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226130947
Principal investigator 1 Genentech, Inc. $17,062.00 05/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211587079
Principal investigator 1 Genentech, Inc. $41,922.00 05/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES O
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211586967
Principal investigator 1 Genentech, Inc. $32,325.00 05/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES O
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211586971
Principal investigator 1 GlaxoSmithKline, LLC. $1,202.40 05/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192175259
Principal investigator 1 SANOFI US SERVICES INC. $140.97 05/05/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226130909
Principal investigator 1 SANOFI US SERVICES INC. $75.00 05/05/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226130926
Principal investigator 1 Boehringer Ingelheim International GmbH $11.29 05/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640773
Principal investigator 1 Boehringer Ingelheim International GmbH $7.08 05/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640775
Principal investigator 1 Boehringer Ingelheim International GmbH $94.42 05/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640777
Principal investigator 1 Boehringer Ingelheim International GmbH $785.00 05/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640785
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 05/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640787
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 05/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY Study) No dispute reported 06/30/2026 1220640789
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 05/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220640943
Principal investigator 1 Genentech, Inc. $51,544.00 04/30/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211587087
Principal investigator 1 SANOFI US SERVICES INC. $11,700.00 04/28/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226130890
Principal investigator 1 SANOFI US SERVICES INC. $1,300.00 04/28/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226130905
Principal investigator 1 Genentech, Inc. $34,124.00 04/25/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211587062
Principal investigator 1 GlaxoSmithKline, LLC. $1,413.60 04/25/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192177061
Principal investigator 1 AstraZeneca Pharmaceuticals LP $37,940.00 04/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES
ANCHOR No dispute reported 06/30/2026 1185555481
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 04/21/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226130881
Principal investigator 1 SANOFI US SERVICES INC. $2,700.00 04/21/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226130886
Principal investigator 1 SANOFI US SERVICES INC. $75.00 04/21/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226130897
Principal investigator 1 SANOFI US SERVICES INC. $5,500.00 04/21/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226130901
Principal investigator 1 SANOFI US SERVICES INC. $1,500.00 04/14/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226130913
Principal investigator 1 SANOFI US SERVICES INC. $900.00 04/14/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226130918
Principal investigator 1 SANOFI US SERVICES INC. $75.00 04/14/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226130922
Principal investigator 1 Genentech, Inc. $15,266.00 04/11/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211587083
Principal investigator 1 SANOFI US SERVICES INC. $4,887.00 04/07/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226130873
Principal investigator 1 Genentech, Inc. $20,654.00 04/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211587070
Principal investigator 1 GlaxoSmithKline, LLC. $722.00 04/04/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192177048
Principal investigator 1 SANOFI US SERVICES INC. $2,399.00 04/02/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226130870
Principal investigator 1 SANOFI US SERVICES INC. $75.00 04/02/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic obstructive pulmonary disease (COPD) who participated in either EFC16750 or EFC16819 clinical studies No dispute reported 06/30/2026 1226130875
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 04/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220640941
Principal investigator 1 Ethicon Inc. $5,000.00 04/01/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CEN TRAL PA LLC
Fluoroscopy Image Acquisition while using the Monarch Platform - Bronchoscopy No dispute reported 06/30/2026 1174996252
Principal investigator 1 Genentech, Inc. $12,572.00 03/28/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211587016
Principal investigator 1 Boehringer Ingelheim International GmbH $39.96 03/25/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220640969
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 03/25/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220640971
Principal investigator 1 Genentech, Inc. $13,470.00 03/21/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211587001
Principal investigator 1 SANOFI US SERVICES INC. $2,279.00 03/17/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226130847
Principal investigator 1 SANOFI US SERVICES INC. $6,281.00 03/10/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226130865
Principal investigator 1 Genentech, Inc. $15,872.00 03/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211587013
Principal investigator 1 GlaxoSmithKline, LLC. $922.00 03/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192179380
Principal investigator 1 Genentech, Inc. $47,434.00 03/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211587024
Principal investigator 1 SANOFI US SERVICES INC. $450.00 03/04/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226130851
Principal investigator 1 SANOFI US SERVICES INC. $5,000.00 03/04/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
ACT - POC clinical study - IL13 x TSLP Nanobody VHH - lunsekimig No dispute reported 06/30/2026 1226130854
Principal investigator 1 SANOFI US SERVICES INC. $1,000.00 03/04/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Pivotal Study to Assess the Efficacy, Safety, and Tolerability of Dupilumab in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) With Type 2 Inflammation No dispute reported 06/30/2026 1226130862
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $650.00 03/03/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220812832
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $650.00 03/03/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220812834
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $605.00 03/03/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220812836
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 03/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220640937
Principal investigator 1 Boehringer Ingelheim International GmbH $299.70 02/25/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220640957
Principal investigator 1 Boehringer Ingelheim International GmbH $255.50 02/25/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220640959
Principal investigator 1 Boehringer Ingelheim International GmbH $488.56 02/25/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220640961
Principal investigator 1 Boehringer Ingelheim International GmbH $103.65 02/25/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220640963
Principal investigator 1 Boehringer Ingelheim International GmbH $13.44 02/25/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220640965
Principal investigator 1 Boehringer Ingelheim International GmbH $57.00 02/25/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220640967
Principal investigator 1 GlaxoSmithKline, LLC. $2,630.55 02/25/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192127785
Principal investigator 1 AstraZeneca Pharmaceuticals LP $230,959.71 02/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES
The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod No dispute reported 06/30/2026 1185555475
Principal investigator 1 GlaxoSmithKline, LLC. $2,500.00 02/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192175243
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $650.00 02/19/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
PhII - BI 1839100 in IPF associated with chronic cough No dispute reported 06/30/2026 1220812880
Principal investigator 1 SANOFI US SERVICES INC. $950.00 02/18/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226130868
Principal investigator 1 AstraZeneca Pharmaceuticals LP $29,649.79 02/17/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES
A Multicenter,Single arm,Open label,Post Authorization,Phase 4 Effectiveness and Safety Study of Tezepelumab in Adult and Adolescent Participants with Severe Asthma including Several Under Studied Populations in the United States No dispute reported 06/30/2026 1185555483
Principal investigator 1 Genentech, Inc. $17,712.00 02/12/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211586997
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $39,203.65 02/10/2025 Non-covered Recipient Entity
Clinical Research Associates of Central
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220812830
Principal investigator 1 Genentech, Inc. $45,671.00 02/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD No dispute reported 06/30/2026 1211587058
Principal investigator 1 GlaxoSmithKline, LLC. $893.00 02/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192177045
Principal investigator 1 GlaxoSmithKline, LLC. $755.00 02/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192177053
Principal investigator 1 GlaxoSmithKline, LLC. $1,736.00 02/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192177057
Principal investigator 1 Genentech, Inc. $21,879.00 02/06/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211587054
Principal investigator 1 Genentech, Inc. $21,326.00 02/05/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211586992
Principal investigator 1 SANOFI US SERVICES INC. $211.00 02/04/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226130843
Principal investigator 1 GlaxoSmithKline, LLC. $798.00 02/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192179384
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 02/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220640935
Principal investigator 1 AstraZeneca Pharmaceuticals LP $22,008.10 01/31/2025 Non-covered Recipient Entity
CLINICAL LABORATORIES OF LINCOLN
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations No dispute reported 06/30/2026 1185555501
Principal investigator 1 Genentech, Inc. $37,848.00 01/31/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211587009
Principal investigator 1 Genentech, Inc. $74,104.00 01/29/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211586988
Principal investigator 1 Boehringer Ingelheim International GmbH $103.65 01/27/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220640951
Principal investigator 1 Boehringer Ingelheim International GmbH $16.80 01/27/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220640953
Principal investigator 1 Boehringer Ingelheim International GmbH $67.00 01/27/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220640955
Principal investigator 1 Boehringer Ingelheim International GmbH $182.50 01/27/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220640973
Principal investigator 1 Boehringer Ingelheim International GmbH $610.70 01/27/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A randomised, double-blind, placebo-controlled, dose-finding study evaluating efficacy, safety, and tolerability of different oral doses of BI 1819479 over at least 24 weeks in patients with idiopathic pulmonary fibrosis (IPF) No dispute reported 06/30/2026 1220640975
Principal investigator 1 Genentech, Inc. $37,804.00 01/24/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211587020
Principal investigator 1 Genentech, Inc. $15,018.00 01/22/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211587029
Principal investigator 1 SANOFI US SERVICES INC. $2,388.00 01/21/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab (Anti-IL-33 mAb) in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226130857
Principal investigator 1 AstraZeneca Pharmaceuticals LP $20,174.71 01/17/2025 Non-covered Recipient Entity
CLINICAL LABORATORIES OF LINCOLN
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) No dispute reported 06/30/2026 1185555477
Principal investigator 1 AstraZeneca Pharmaceuticals LP $27,190.26 01/17/2025 Non-covered Recipient Entity
CLINICAL LABORATORIES OF LINCOLN
A Phase III Multicentre Randomised Double blind Chronic dosing Parallel group Placebo controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease COPD with a History of COPD Exacerbations OBERON No dispute reported 06/30/2026 1185555499
Principal investigator 1 Genentech, Inc. $52,260.00 01/13/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1211587005
Principal investigator 1 GlaxoSmithKline, LLC. $2,529.00 01/13/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA
A 52-WEEK, RANDOMISED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL GROUP, MUL No dispute reported 06/30/2026 1192179372
Principal investigator 1 Genentech, Inc. $2,600.00 01/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211587033
Principal investigator 1 Genentech, Inc. $15,557.00 01/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211587041
Principal investigator 1 Genentech, Inc. $5,218.00 01/09/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211587050
Principal investigator 1 Genentech, Inc. $486.59 01/07/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
Ph III OLE of Astegolimab in COPD No dispute reported 06/30/2026 1211587038
Principal investigator 1 SANOFI US SERVICES INC. $2,099.00 01/06/2025 Non-covered Recipient Entity
Clinical Research Associates Of Central PA LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof-of-Concept (PoC) Study to Assess the Efficacy, Safety and Tolerability of Itepekimab, in Participants With Non-cystic Fibrosis Bronchiectasis No dispute reported 06/30/2026 1226130878
Principal investigator 1 Genentech, Inc. $1,500.00 01/03/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PA LLC
A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamic Effects Of GDC-6599 In Patients With Chronic Cough No dispute reported 06/30/2026 1211587045
Principal investigator 1 Amgen Inc. $52,185.20 01/02/2025 Non-covered Recipient Entity
CLINICAL RESEARCH ASSOCIATES OF CENTRAL PENNSYLVANIA
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma No dispute reported 06/30/2026 1246640307
Principal investigator 1 Boehringer Ingelheim International GmbH $43.52 01/01/2025 Non-covered Recipient Entity
Penn Highlands Du Bois Emergency Department And Trauma Center
A Phase IIa/IIb, randomised, double blind, placebo-controlled, parallel-group dose-finding study to examine the efficacy and safety of BI 1839100 administered orally over a 12-week treatment period in patients with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis with clinically meaningful cough No dispute reported 06/30/2026 1220640939